BCDA CEO Peter Altman Buys More Shares, Continuing Recent Activity
Peter Altman, CEO of BCDA, purchased 800 shares at $0.96 each on June 18, 2026.
Key Points
- Peter Altman, CEO of BCDA, bought 800 shares at $0.96 per share on June 18, 2026.
- Shares of BCDA traded near $0.97 on Monday, with notable institutional interest from firms like Vanguard and Geode Capital.
- HC Wainwright & Co. reiterated its buy rating on BCDA with a $25 price target on June 9, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Peter Altman, the President and CEO of BCDA, purchased 800 shares of the company at an average price of $0.96 on June 18, 2026. This insider buying follows a series of recent acquisitions by Altman, highlighting his ongoing confidence in the company's prospects.
Insider Buying and Selling at BioCardia, Inc.
Peter Altman has been actively buying shares of BCDA. On June 18, 2026, he bought 800 shares at $0.96 each, adding to his previous purchases of 1,500 shares at $0.85 on June 17, 2026, and 5,000 shares at $0.85 on June 9, 2026. These transactions were not part of a pre-arranged trading plan, indicating his proactive investment approach.
Other Institutional Activity in BCDA
Institutional investors have shown varied interest in BCDA. Vanguard Capital Management LLC opened a new position with 124,591 shares valued at about $150,755. Geode Capital Management, LLC increased its holdings by 28,284 shares, now holding 94,287 shares worth approximately $114,086, marking a 42.9% increase. Conversely, Citadel Advisors LLC reduced its stake by 30,863 shares, ending with 63,384 shares valued at $76,695, a 32.7% decrease.
BioCardia, Inc. Stock Down 17.8%
Shares of BCDA traded near $0.97 on Monday. The company has attracted attention from both insiders and institutional investors. While specific financial metrics were not provided, the stock's recent insider and institutional activities suggest ongoing interest and potential future developments.
$BCDA stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 9, 2026, HC Wainwright & Co. reiterated its buy rating for BCDA with a price target of $25. This reflects continued confidence from analysts in the company's future performance.
Bottom Line
Peter Altman's recent share purchases add to a pattern of insider confidence in BCDA. Institutional investors have also shown varied interest, with some increasing their stakes significantly. Analysts at HC Wainwright & Co. maintain a positive outlook on the stock, reinforcing its potential in the market.
Get BioCardia, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BCDA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.